Top Cancer Diagnostics Companies

Global Cancer Diagnostics Market size was valued at USD 21.6 billion in 2023 and is poised to grow from USD 23.63 billion in 2024 to USD 48.49 billion by 2032, growing at a CAGR of 9.4% during the forecast period (2025-2032).

The cancer diagnostics market is experiencing dynamic shifts, with companies adopting innovative strategies to gain a competitive edge. Guardant Health has expanded its market reach by securing Medicare coverage for its colon cancer blood test, Guardant Reveal, leading to a significant stock surge and positioning the company as a leader in blood-based cancer detection. Exact Sciences is intensifying competition by developing a blood test that detected 88.3% of cancers and 31.2% of advanced adenomas in a study, potentially surpassing Guardant's offerings. Meanwhile, startups like Dxcover and Quibim are introducing AI-driven diagnostics and imaging biomarkers, respectively, aiming to disrupt traditional diagnostic methods and offer more precise, early detection solutions.'Abbott Laboratories (USA)', 'F. Hoffmann-La Roche Ltd (Switzerland)', 'Siemens Healthineers (Germany)', 'Thermo Fisher Scientific Inc. (USA)', 'GE Healthcare (USA)', 'Hologic Inc. (USA)', 'Illumina Inc. (USA)', 'Bio-Rad Laboratories Inc. (USA)', 'Agilent Technologies Inc. (USA)', 'bioMérieux SA (France)', 'Myriad Genetics Inc. (USA)', 'Qiagen N.V. (Netherlands)', 'PerkinElmer Inc. (USA)', 'Danaher Corporation (USA)'

The increasing global burden of cancer is a major driver for the cancer diagnostics market. According to the WHO, cancer accounted for nearly 10 million deaths in 2020, and the number of new cases is expected to grow significantly in the coming decades. This surge necessitates early detection and accurate diagnosis to improve survival rates and reduce treatment costs. Consequently, governments and health organizations are investing heavily in screening programs and awareness campaigns. The growing demand for timely diagnosis is pushing the development and adoption of novel diagnostic tools, especially in both high-income and developing countries.

Integration of Artificial Intelligence in Diagnostic Workflows: AI is increasingly being embedded into cancer diagnostics, significantly enhancing accuracy and speed in image analysis, histopathology, and risk stratification. Tools like AI-based imaging platforms and decision-support systems are streamlining workflows and reducing diagnostic errors. Governments and healthcare providers are investing in pilot programs—such as Telangana’s AI-based screening in India—highlighting growing trust in AI-driven tools for early detection, especially in resource-limited settings.

North America leads the global cancer diagnostics market, propelled by advanced healthcare infrastructure, significant R&D investments, and a high prevalence of cancer. The region's dominance is further strengthened by the presence of major market players and supportive government initiatives.